Full Length Research Paper
References
|
Al-Tawfiq JA, Abukhamsin A (2009). A 24-year study of the epidemiology of human brucellosis in a health-care system in Eastern Saudi Arabia. J. Infect. Public Health. 2(2):81-85. Crossref |
||||
| Alton GG, Jones LM, Angus RD, Verger JM (1988). Techniques for the brucellosis Laboratory. Paris: Institut National de la recherche Agronomique (INRA). pp. 34-61. | ||||
|
Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B (2004). In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents. 23:405-407. Crossref |
||||
|
Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, Berktas (2011). Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Specimens. Int. J. Med. Sci. 8(3): 198-202. Crossref |
||||
| Black TF (2004). Brucellosis. In: Cohen J, Powderly WG; Infectious diseases; 2nd ed. St Louis: Mosby. pp. 1665-1667. | ||||
|
Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, Erbay A (2003). Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J. Infect. Dis. 35(5):337-338. Crossref |
||||
| Clinical and Laboratory Standards Institute (CLSI) (2006). Performance standards for antimicrobial susceptibility testing; Sixteenth informational supplement; CLSI document M 100S16. Wayne, PA, USA: CLSI. | ||||
|
De Rautlin de la Roy YM, Grignon B, Grollier G, Coindreau MF, Becq-Giraudon B (1986). Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin. J. Antimicrob. Chemother. 18:648-649. Crossref |
||||
|
Dizbay M, Kilic S, Hizel K, Arman D (2007). Tigecycline: its potential for treatment of brucellosis. Scand J. Infect. Dis. 39(5):432-434. Crossref |
||||
|
Elbeltagy KE (2001). An epidemiological profile of brucellosis in Tabuk Province, Saudi Arabia. East Mediter. Health J. 7(4-5):791-8. |
||||
|
Fallatah SM, Oduloju AJ, Al-Dusari SN, Fakunle YM (2005). Human brucellosis in Northern Saudi Arabia. Saudi Med. J. 26(10):1562-6. Pubmed |
||||
|
Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I (1991). Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother. 35:756-759. Crossref |
||||
|
Gür D, Kocagöz S, Akova M, Ünal S (1999). Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicr. Agents Chemother. 43(9):2337. Pubmed |
||||
| Joint Food and Agriculture Organization/World Health Organization (1986). FAO-WHO Expert Committee on Brucellosis (sixth report). WHO Technical Report Series No. 740. Geneva: World Health Organisation. pp. 56-57. | ||||
|
Kilic S, Dizbay M, Cabadak H (2008). In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis. J. Chemother. 20(1):33-37. Crossref |
||||
| Kilic S, Dizbay M, Hizel K, Arman D (2008). In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology. Braz J. Mic. 39:1-7. | ||||
|
King A (2001). Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J. Antimicrob. Chemother. 48(Suppl S1):S77-S80. Crossref |
||||
| Kinsara A, Al-Mowallad A, Osoba OA (1999). Increasing resistance of Brucellae to co-trimoxazole. Antimicrob. Agents Chemother. pp. 43:1531. | ||||
|
Köse S, Kiliç S, Ozbel Y (2005). Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey. J. Basic Microbiol. 45(4):323-327. Crossref |
||||
|
Livermore DM (2005). Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56:611-614. Crossref |
||||
|
Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Guttierrez-Rubio AT, Cardenosa O (2004). Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand. J. Infect Dis. 36:636-638. Crossref |
||||
|
Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R (2004). Genetic bases of the rifampin resistance phenotype in Brucella spp. J. Clin. Microbiol. 42:5439-5443. Crossref |
||||
|
Marianelli C, Graziani C, Santangelo C, Xibilia MiT, Imbriani A, Amato R, Neri D, Cuccia M, Rinnone S, Di Marco V, Ciuchini F (2007). Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily, Italy. J. Clin. Microbiol. 45(9):2923-2928. Crossref |
||||
|
Mile B, Valerija K, Krsto G, Ivan V, Ilir D, Nikola L (2012). Doxycycline-rifampin versus doxycycline-rifampin-gentamicin in treatment of human brucellosis. Trop. Doct. 42(1):13-17 Crossref |
||||
|
Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). Brucellosis. N. Engl. J. Med. 352:2325-2336. Crossref |
||||
|
Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV (2006). The new global map of human brucellosis. Lancet Infect. Dis. 6:91-99. Crossref |
||||
|
Pappas G, Solera J, Akritidis N, Tsianos E (2008). New approaches to the antibiotic treatment of brucellosis. Int. J. Antimicrob. Agents. 26:101-105. Crossref |
||||
|
Qadri SM, Halim MA, Ueno Y, Abumustafa FM, Postle AG (1995). Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy 41(4):253-256. Crossref |
||||
| Shapiro SD, Wong JD. Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (2001). Manuel of clinical microbiology, Washington DC: ASM Press; 1(7):625-631. | ||||
|
Turkmani A, Ionnidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y (2006). In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann. Clin. Microbiol. Antimicrob. 5:24. Crossref |
||||
| Young EJ (2005). Brucella species. In: Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases, 6th ed. Philadelphia: Churchill Livingstone, pp. 2669-2672. | ||||
|
Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ (2006). Tigecycline: a novel glycylcycline antibiotic. Expert Rev. AntiInfect Ther. 4:9-25. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
